CN101376910A - 微小rna基因在系统性红斑狼疮疾病诊断和治疗中的作用 - Google Patents
微小rna基因在系统性红斑狼疮疾病诊断和治疗中的作用 Download PDFInfo
- Publication number
- CN101376910A CN101376910A CNA200810095841XA CN200810095841A CN101376910A CN 101376910 A CN101376910 A CN 101376910A CN A200810095841X A CNA200810095841X A CN A200810095841XA CN 200810095841 A CN200810095841 A CN 200810095841A CN 101376910 A CN101376910 A CN 101376910A
- Authority
- CN
- China
- Prior art keywords
- ribonucleic acid
- micro ribonucleic
- expression
- mir
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/10—Applications; Uses in screening processes
- C12N2320/12—Applications; Uses in screening processes in functional genomics, i.e. for the determination of gene function
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Plant Pathology (AREA)
- Epidemiology (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
名称 | 序列(GenBank登录号) | SEQ ID NO: |
miR-146a | 5’UGAGAACUGAAUUCCAUGGGUU 3’(MI0000477) | 2 |
miR-130b | 5’CAGUGCAAUGAUGAAAGGGCAU 3’(MI0000748) | 4 |
miR99a | 5’AACCCGUAGAUCCGAUCUUGUG 3’(MI0000101) | 5 |
miR-10a | 5’UACCCUGUAGAUCCGAAUUUGUG 3’(MI0000266) | 6 |
miR-134 | 5’UGUGACUGGUUGACCAGAGGGG 3’(MI0000474) | 7 |
miR-31 | 5’AGGCAAGAUGCUGGCAUAGCU 3’(MI0000089) | 8 |
miR-95 | 5’UUCAACGGGUAUUUAUUGAGCA 3’(MI0000097) | 9 |
Claims (10)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200810095841XA CN101376910B (zh) | 2007-08-27 | 2008-04-30 | 微小rna基因在系统性红斑狼疮疾病诊断和治疗中的作用 |
PCT/CN2008/072159 WO2009030153A1 (fr) | 2007-08-27 | 2008-08-27 | Rôles de micro-arn dans le diagnostic et le traitement du lupus érythémateux systémique |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200710045278.0 | 2007-08-27 | ||
CN200710045278 | 2007-08-27 | ||
CN200810095841XA CN101376910B (zh) | 2007-08-27 | 2008-04-30 | 微小rna基因在系统性红斑狼疮疾病诊断和治疗中的作用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101376910A true CN101376910A (zh) | 2009-03-04 |
CN101376910B CN101376910B (zh) | 2012-01-11 |
Family
ID=40420649
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200810095841XA Active CN101376910B (zh) | 2007-08-27 | 2008-04-30 | 微小rna基因在系统性红斑狼疮疾病诊断和治疗中的作用 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN101376910B (zh) |
WO (1) | WO2009030153A1 (zh) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012031412A1 (zh) * | 2010-09-08 | 2012-03-15 | 上海市公共卫生临床中心 | 用于预测干扰素治疗慢性乙型肝炎疗效的血浆miRNA谱及检测试剂盒 |
CN102813926A (zh) * | 2012-08-10 | 2012-12-12 | 中国医学科学院北京协和医院 | miR-7表达抑制剂在制备治疗系统性红斑狼疮药物中的应用 |
CN102078621B (zh) * | 2009-11-27 | 2013-04-10 | 中国科学院上海生命科学研究院 | 调控浆细胞样树突状细胞i型干扰素表达的方法和组合物 |
CN110387411A (zh) * | 2018-04-23 | 2019-10-29 | 长庚医疗财团法人高雄长庚纪念医院 | 用于检测狼疮性肾炎或评估狼疮性肾炎风险的方法及其应用 |
CN111378742A (zh) * | 2020-04-16 | 2020-07-07 | 嘉兴程瑞医药科技有限公司 | microRNA生物标志物及其在制备自身免疫疾病检测试剂盒中的应用 |
CN111603477A (zh) * | 2019-02-25 | 2020-09-01 | 中国科学院分子细胞科学卓越创新中心 | 环形rna在系统性红斑狼疮制备治疗药物中的应用 |
CN111965358A (zh) * | 2013-02-08 | 2020-11-20 | 阿勒格尼-辛格研究所 | 细胞结合的补体激活产物作为狼疮前期诊断性生物标志物 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20140066671A (ko) * | 2011-06-27 | 2014-06-02 | 메디뮨 엘엘씨 | 자가면역 질환에서 사용되는 마이크로rna-31 조성물 및 방법 |
WO2013030841A1 (en) * | 2011-09-04 | 2013-03-07 | Yissum Research Development Company Of The Hebrew Universitiy Of Jerusalem Ltd. | Prognostic methods and compositions for predicting interferon treatment eficacy in a subject |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2471924A1 (en) * | 2004-05-28 | 2012-07-04 | Asuragen, INC. | Methods and compositions involving microRNA |
CA2850323A1 (en) * | 2004-11-12 | 2006-12-28 | Asuragen, Inc. | Methods and compositions involving mirna and mirna inhibitor molecules |
-
2008
- 2008-04-30 CN CN200810095841XA patent/CN101376910B/zh active Active
- 2008-08-27 WO PCT/CN2008/072159 patent/WO2009030153A1/zh active Application Filing
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102078621B (zh) * | 2009-11-27 | 2013-04-10 | 中国科学院上海生命科学研究院 | 调控浆细胞样树突状细胞i型干扰素表达的方法和组合物 |
WO2012031412A1 (zh) * | 2010-09-08 | 2012-03-15 | 上海市公共卫生临床中心 | 用于预测干扰素治疗慢性乙型肝炎疗效的血浆miRNA谱及检测试剂盒 |
CN102813926A (zh) * | 2012-08-10 | 2012-12-12 | 中国医学科学院北京协和医院 | miR-7表达抑制剂在制备治疗系统性红斑狼疮药物中的应用 |
CN102813926B (zh) * | 2012-08-10 | 2014-07-02 | 中国医学科学院北京协和医院 | miR-7表达抑制剂在制备治疗系统性红斑狼疮药物中的应用 |
CN111965358A (zh) * | 2013-02-08 | 2020-11-20 | 阿勒格尼-辛格研究所 | 细胞结合的补体激活产物作为狼疮前期诊断性生物标志物 |
CN110387411A (zh) * | 2018-04-23 | 2019-10-29 | 长庚医疗财团法人高雄长庚纪念医院 | 用于检测狼疮性肾炎或评估狼疮性肾炎风险的方法及其应用 |
JP2019187413A (ja) * | 2018-04-23 | 2019-10-31 | チャン グァン メモリアル ホスピタル,カオシュン | ループス腎炎の検出またはそのリスクを予測する方法およびその応用 |
CN111603477A (zh) * | 2019-02-25 | 2020-09-01 | 中国科学院分子细胞科学卓越创新中心 | 环形rna在系统性红斑狼疮制备治疗药物中的应用 |
CN111603477B (zh) * | 2019-02-25 | 2023-06-02 | 中国科学院分子细胞科学卓越创新中心 | 环形rna在系统性红斑狼疮制备治疗药物中的应用 |
CN111378742A (zh) * | 2020-04-16 | 2020-07-07 | 嘉兴程瑞医药科技有限公司 | microRNA生物标志物及其在制备自身免疫疾病检测试剂盒中的应用 |
Also Published As
Publication number | Publication date |
---|---|
CN101376910B (zh) | 2012-01-11 |
WO2009030153A1 (fr) | 2009-03-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101376910B (zh) | 微小rna基因在系统性红斑狼疮疾病诊断和治疗中的作用 | |
Moran-Moguel et al. | Rheumatoid arthritis and miRNAs: a critical review through a functional view | |
Nakasa et al. | Expression of microRNA‐146 in rheumatoid arthritis synovial tissue | |
Doghish et al. | miRNAs insights into rheumatoid arthritis: Favorable and detrimental aspects of key performers | |
Long et al. | Upregulated microRNA‐155 expression in peripheral blood mononuclear cells and fibroblast‐like synoviocytes in rheumatoid arthritis | |
Liu et al. | CCL5 promotes VEGF-dependent angiogenesis by down-regulating miR-200b through PI3K/Akt signaling pathway in human chondrosarcoma cells | |
Xia et al. | microRNA-146b inhibits glioma cell migration and invasion by targeting MMPs | |
CN1922332B (zh) | 预测并克服对卵巢癌化疗的抗性的方法及预测结肠癌发生的方法 | |
CN102421917B (zh) | 对抗、预防和/或测定心力衰竭或心力衰竭的风险的工具和方法 | |
EP2719773A2 (en) | mRNA as marker for acute lamphomic leucemia | |
US9624491B2 (en) | Methods and compositions for the detection and treatment of cancer involving miRNAs and miRNA inhibitors and targets | |
EP2077326A1 (en) | Novel nucleic acid | |
Zhang et al. | lncRNA IGHCγ1 Acts as a ceRNA to Regulate Macrophage Inflammation via the miR‐6891‐3p/TLR4 Axis in Osteoarthritis | |
Chen et al. | miR‐378a modulates macrophage phagocytosis and differentiation through targeting CD47‐SIRPα axis in atherosclerosis | |
Makino et al. | Genetic and epigenetic abnormalities in systemic sclerosis | |
CN104080924A (zh) | 用于治疗和诊断乳腺癌的方法和组合物 | |
Hong et al. | The effects of microRNAs on key signalling pathways and epigenetic modification in fibroblast‐like synoviocytes of rheumatoid arthritis | |
US20180289692A1 (en) | Tlr modulators and methods of use | |
Zou et al. | LncRNA THRIL is involved in the proliferation, migration, and invasion of rheumatoid fibroblast-like synoviocytes | |
US20140045924A1 (en) | Melanoma treatments | |
Tu et al. | MicroRNA-10b promotes arthritis development by disrupting CD4+ T cell subtypes | |
CN103826623A (zh) | 合成致死与癌症的治疗 | |
KR102142791B1 (ko) | miR-204 억제제의 골관절염 치료 용도 | |
Morlang et al. | Cutaneous microRNA expression in healthy Labrador and Golden retrievers and retrievers with allergic and inflammatory skin diseases | |
US20220135979A1 (en) | Diagnosis and treatment of medulloblastoma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C53 | Correction of patent for invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: Shen Nan Inventor after: Tang Yuanjia Inventor after: Cui Huijuan Inventor after: Luo Xiaobing Inventor after: Ni Xuming Inventor after: Liang Dong Inventor before: Shen Nan Inventor before: Tang Yuanjia Inventor before: Cui Huijuan Inventor before: Luo Xiaobing Inventor before: Ni Xuming |
|
COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: SHEN NAN TANG YUANJIA CUI HUIJUAN LUO XIAOBING NI XUMING TO: SHEN NAN TANG YUANJIA CUI HUIJUAN LUO XIAOBING NI XUMING LIANG DONG |
|
CP03 | Change of name, title or address |
Address after: 200031 Yueyang Road, Shanghai, No. 319, No. Patentee after: Shanghai Institute of nutrition and health, Chinese Academy of Sciences Address before: 200031 No. 320, Yueyang Road, Shanghai Patentee before: SHANGHAI INSTITUTES FOR BIOLOGICAL SCIENCES, CHINESE ACADEMY OF SCIENCES |
|
CP03 | Change of name, title or address |